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Abstract
Rheumatoid arthritis (RA) is an inflammatory, polyarticular joint disease. A number of cellular responses are involved
in the pathogenesis of rheumatoid arthritis, including activation of inflammatory cells and cytokine expression. The
cellular responses involved in each of these processes depends on the specific signaling pathways that are
activated; many of which include protein tyrosine kinases. These pathways include the mitogen-activated protein
kinase pathway, Janus kinases/signal transducers and activators transcription pathway, spleen tyrosine kinase
signaling, and the nuclear factor -light-chain-enhancer of activated B cells pathway. Many drugs are in
development to target tyrosine kinases for the treatment of RA. Based on the number of recently published
studies, this manuscript reviews the role of tyrosine kinases in the pathogenesis of RA and the potential role of
kinase inhibitors as new therapeutic strategies of RA.
Introduction
Rheumatoid arthritis (RA) is a destructive, inflammatory,
polyarticular joint disease with an etiology that remains
to be fully elucidated. RA is characterized by massive
synovial proliferation and subintimal infiltration of
inflammatory cells, followed by the destruction of carti-
lage and bone [1]. A number of cellular responses are
involved in the pathogenesis of RA, including activation
of inflammatory cells and expression of various cyto-
kines. Macrophages, T cells, B cells and neutrophils
migrate into synovial tissue and activate these cells to
produce both inflammatory and degradative mediators
that break down the extracellular matrix of cartilage.
Synovial cells undergo hyperplasia, and angiogenesis
occurs in synovial tissues further promoting inflamma-
tion. Although synoviocyte proliferation contributes to
the hyperplastic response of synovial tissue in RA, syno-
vial tissue hyperplasia must also be a result of the
recruitment, retention and attachment of mast cells,
neutrophils, and lymphocytes to the inflamed tissue as
well as the stimulus of neoangiogenesis. Inflammatory
mediators such as interleukin-6 (IL-6), interleukin-1 (IL-
1) and tumor necrosis factor-a (TNF-a) play important
roles in the pathogenesis of RA. These cytokines are
abundant in synovial tissues and fluid from RA patients
and overexpression of the cytokines mentioned above
promote chronic inflammation and joint destruction [2].
These cytokines have emerged as dominant pro-inflam-
matory mediators and important molecular targets for
therapy [3]. TNF-a and IL-1 has been reported to stimu-
late synovial cells to release VEGF which has important
role in the angiogenesis observed in RA pathology [4,5].
Classically, immune responses are regulated by two sub-
types of CD4 + T helper (Th) cells, designated Th1 and
Th2. Th1 cells produce interferon- (IFN-g) and interleu-
kin-2 (IL-2), which are known to be important media-
tors of organ-specific autoimmune disorders. On the
other hand, Th2 cells produce the cytokines IL-4, IL-5,
IL-9, and IL-13, which are responsible for promoting
the development of atopic allergy. RA has been reported
to be a Th1 and not a Th2 associated disorder. At pre-
sent, RA is thought to be a Th1 and/or Th17 mediated
disorder. Th17 cells are relatively new subset of helper
T cells and are characterized by expression of RORgta s
a master regulator gene as well as secretion of IL-17A,
IL-17F, IL-21 and IL-22 [6]. Human T-regulatory (Treg)
cells were reported to differentiate to IL-17 producing
cells [7]. Treg and Th17 cells appear to be associated as
both of these cells are induced by TGF-beta and also
express Th17-associated trascription factor RORgt. Th1
cells are also associated with Treg cells and Th17 cells,
as the gene encoding for T-bet, the master regulator of
Th1 differentiation, was found to be in an active state,
according to histone methylationmarks, in both Th17
and Treg cells [8]. This observation indicated that Th17
and Treg cells remain to have the potential to
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towards Th1 cells.
The activation and function of these inflammatory
cells depend on specific signaling pathways; many of
which involve protein tyrosine kinases. Proteins from
the synovial tissue of RA patients have been reported to
be extensively phosphorylated by intracellular tyrosine
kinases, supporting the importance of tyrosine kinases
in the pathogenesis of RA [9]. These pathways include
the mitogen-activated protein kinase (MAPK) pathway,
the Janus kinases (JAK)/signal transducers and activators
of transcription (STAT) pathway, spleen tyrosine kinase
(Syk) signaling, and the nuclear factor -light-chain-
enhancer of activated B cells (NF-B) pathway
In fact, many drugs are in development to target tyro-
sine kinases for the treatment of RA. Based on the num-
ber of recently published studies, this review focuses on
t h er o l eo ft y r o s i n ek i n a s e si nt h ep a t h o g e n e s i so fR A
and potential role of kinase inhibitors as new therapeu-
tic strategies for RA.
Mitogen-Activated Protein Kinases
The serine/threonine MAPK pathway is activated in RA
patients. Initiated by cytokine receptors, Toll-like recep-
tors, and other danger signals, the pathway begins with the
MAPK kinase kinases (MAP3K), which phosphorylate and
activate the MAPK kinases (MKK), which in turn phos-
phorylate MAPK, leading to the activation of various tran-
scription factors [10]. The MAPK include extracellular
signal-regulated kinases (ERK) and the p38 kinase (p38).
ERK1 and 2, activated by signaling from growth factor
receptors and certain cytokine receptors, activate the tran-
scription factors Elk-1 and c-Myc (Figure 1). The kinases
p38a and p38b are typically activated by signaling from
Toll-like receptors, as well as in response to oxidative
stress, inflammatory cytokines, etc. The role of MAPK in
transmitting signals from inflammatory cytokines such as
TNF-a, which have proven to be successful targets in the
treatment of RA, have made the MAPKs themselves
attractive targets for the development of new therapies.
However, the results from two 12-week studies on a p38a
inhibitor, VX-702 (Vertex Pharmaceuticals; Cambridge,
MA) were disappointing. Despite a trend toward an
increased percentage of patients meeting the American
College of Rheumatology (ACR) 20% improvement criteria
(ACR20) in the treatment groups receiving the drug com-
pared with placebo, the data were not statistically signifi-
cant [11]. Furthermore, there was no discernable dose-
dependent effect of the drug when patients were also trea-
ted with methotrexate. In addition, an increased incidence
of adverse events was observed in the treatment (Cam-
bridge, MA) groups compared with placebo, particularly
skin rash. In addition, a slight increase in the percentage
of patients with alanine transaminase (ALT) elevation was
also noted. Pamapimod (RO4402257; Hoffmann-La
Roche, Basel, Switzerland), a p38a inhibitor with very low
p38b inhibitory activity, is another drug tested for poten-
tial efficacy against RA. In spite of the promising preclini-
cal data with pamapimod, disappointing results in clinical
studies are reported [12]. Thus far, inhibitors of MAP
kinases have largely failed in clinical trials due to both lack
of efficacy and adverse events. These results indicated that
p38 may play a significant role in homeostasis as well as in
disease states and its inhibition threrfore results in unac-
ceptable side effects. Other targets in the MAPK pathway
are also under investigation. ARRY-162 is an inhibitor of
the MAPK extracellular signal-regulated kinase (MEK).
Phase 1 studies demonstrated that this drug was able to
inhibit 12-O-tetradecanoylphorbol-13-acetate-induced IL-
1b TNF, and IL-6 production ex vivo. Phase 2 studies are
under way in patients with RA. Some evidence suggests
that in addition to inhibition of cytokine production, the
drug blocks osteoclast differentiation and reduces bone
resorption [13].
Janus kinases
Janus kinase (JAKs) binds the cytoplasmic region of
transmembrane-cytokine receptors. After receptor-
ligand interactions, various JAKs are activated, resulting
in tyrosine phosphorylation of the receptor and subse-
quent activation of STATs (signal transducer and activa-
tors of transcription), which act as transcription facotrs
[14]. The STATs are phosphorylated by JAK, dissociate,
Figure 1 Tyrosine kinases involved in the signal transduction
pathways in rheumatoid arthritis. Various tyrosine kinases have
important roles in the pathogenesis of RA and these kinases are
possible targets for the anti-RA strategy. MAP3K: MAPK kinase
kinases, MKK: MAPK kinases, MAPK: mitogen-activated protein kinase,
ERK: extracellular signal-regulated kinases, Syk: spleen tyrosine
kinase, NF-B: nuclear factor -light-chain-enhancer of activated B
cells, IKK: IB kinase, JAK: the Janus kinases, STAT: signal transducers
and activators of transcription.
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nucleus, where they initiate transcription of target genes
(Figure 1). JAKs consist of four types: JAK1, JAK2, JAK3
and TyK2. Hormone-like cytokines (growth hormone,
prolactin, erythropoietin (Epo), and thrombopoietin),
GM-CSF, IL-3 and IL-5 use Jak2. IL-6, IL-10, IL-11, IL-
19, IL-20 IL-22 and interferon (IFN)-g use Jak1 and
Jak2. Mice lacking Jak1 and Jak2 resulted in perinatal
and embryonic lethality respectively. In contrast,
humans and mice lacking Jak3 present with a distinct
primary immunodeficiency disorder designated T-B
+NK- severe combined immunodeficiency (SCID)
[15,16]. Jak3 is the only Jak family member that associ-
ates with just one cytokine receptor-the common g
chain, which is exclusively used by the receptors for IL-
2, IL-4, IL-7, IL-9, IL-15 and IL-21. These cytokines are
critically involved in T and NK cell development and B
cell function and proleferation [17]. By contrast, com-
mongchain-dependent cytokines are not important for
the development or function of organs or tissue outside
the immune system. Thus, a specific Jak3 inhibitor
should have limited but precise effects on immune sys-
tem cells and should leave other cell types unaffected.
Tyk2 has broader functions than Jak3, as it binds to a
number of cytokine receptor subunits. Tyk2-knockout
mice are viable but have reduced sensitivity to interfer-
ons, IL-12 and IL-23. This results in increased suscept-
ibility to some microbial pathogens. One patient with a
Tyk2 deficiency has been described, whose cells were
found to have impaired signaling in response to type I
IFNs, IL-12, IL-23, IL-10 and IL-6. This patient had a
primary immunodeficiency disorder characterized as a
hyper-IgE-like syndrome with multiple, opportunistic
infections with viruses, bacteria and fungi [18]. Suppres-
sor of cytokine signaling (SOCS) proteins and cytokine
inducible SH2-containing (CIS; also known as CISH)
protein molecules comprise a family of intracellular pro-
teins, several of which have been shown to regulate the
responses of immune cells to cytokines.8-10 There are
eight CIS/SOCS family proteins; CIS, SOCS1, SOCS2,
SOCS3, SOCS4, SOCS5, SOCS6, and SOCS7. In addi-
tion to their ability to suppress signaling by ubiquitin-
mediated degradation of the signaling complex, both
SOCS1 and SOCS3 can inhibit JAK tyrosine kinase
activity directly through their kinase inhibitory region
(KIR), which has been proposed to function as a pseu-
dosubstrate and which is important for the suppression
of cytokine signals. Il-6 is one of the cytokines impor-
tant for RA pathology and Il-6 binds to the IL-6 recep-
tor a chain and to gp130. SOCS3 is a relatively specific
inhibitor of gp130 and SOCS3 has been shown to nega-
tively regulate Th17 development by the suppression of
STAT3 activated by IL-6 or IL-23 [19]. There is a report
showing that overexpression of SOCS3 by adenovirus
gene transfer prevented the development of experimen-
tal arthritis [20]. Because of the significant role IL-6
plays in RA pathogenesis, and other evidence suggesting
that the JAK/STAT pathway contributes to the disease,
several JAK inhibitors have been developed and clinical
trials are under way [21]. The most studied candidate in
this pathway is CP- 690,550 (Pfizer; New York, NY), a
small molecule that predominantly blocks JAK3 [22].
CP-690 550 is an orally available JAK antagonist and is
a potent, selective inhibitor of the JAK family of kinases
with selectivity for JAK1/3 over JAK2. Double blind ran-
domized, placebo controlled clinical trials (RCTs) evalu-
ating CP-690 550 have been conducted. In one study,
264 patients were randomized equally to receive pla-
cebo, 5 mg of CP-690,550, 15 mg of CP-690,550, or 30
mg of CP-690,550 twice daily for 6 weeks, and were fol-
lowed up for an additional 6 weeks after treatment. By
week 6, the ACR20 response rates were 70.5%, 81.2%,
and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily
groups respectively, compared with 29.2% in the placebo
group (P < 0.001). Improvements in disease activity in
CP-690,550-treated patients compared with placebo
were seen in all treatment groups as early as week 1. No
opportunistic infections or deaths occurred [23]. In
another study, patients were randomized equally to pla-
cebo, CP-690,550 5, 15 or 30 mg twice daily for 6
weeks, with 6 weeks’ follow-up. The patient’s assessment
of arthritis pain (pain), patient’s assessment of disease
activity, Health Assessment Questionnaire-Disability
Index (HAQ-DI) and Short Form-36 (SF-36) were
recorded. At week 6, significantly more patients in the
CP-690,550 5, 15 and 30 mg twice-daily groups experi-
enced a 50% decrease in pain compared with placebo,
clinically meaningful reductions in HAQ-DI and clini-
cally meaningful improvements in SF-36 domains and
physical and mental components [24]. Taken together,
JAK inhibitors are promising for the treatment of RA
and further clinical studies are ongoing.
Spleen tyrosine kinase (Syk)
Syk is one of the important non-receptor-type protein
tyrosine kinases (PTKs) and was originally isolated from
a porcine spleen cDNA library. Syk is widely expressed
in cells of the hematopoietic system;most notably in B
cells. Various specialized domains such as Src homology
2 (SH2), SH3 and SH4 are defined by non- receptor
PTKs and are involved in the regulation of PTK activity
and interaction with other molecules in signaling path-
way. Tandem SH2 domains of Syk family PTKs selec-
tively bind to diphosphorylated immunoreceptor
tyrosine-based activating motif (ITAM) of the cytoplas-
mic region of immune receptors, such as the T and B
cell receptors. Cbl functions as a ubiquitin ligase
towards Syk and that ubiquitylated Syk is targeted for
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regulator of Syk [25]. Because of its apparent critical
role in regulating T-cell and B-cell expansion and the
proliferation of cells containing the Fcg-activating recep-
tor as well as mediating immunoreceptor signaling in
inflammatory cells and immune complex-mediated sig-
nal transduction, SyK must be considered a promising
target for designing interventional drugs for the treat-
ment of immune-mediated inflammatory arthritis. Syk
activation activates downstream MAPKs and PI3K,
resulting in the increase of IL-6 and MMP production
(Figure 1). Syk is present in the synovium of patients
with RA, and activation of Syk is important for cytokine
and metalloproteinase production induced by TNF-a in
fibroblast-like synoviocyt e sf r o mp a t i e n t sw i t hR A .I n
murine model of human RA, Pine et al. showed that
R788(fostamatinib disodium), an oral prodrug that is
rapidly converted to a potent and relatively selective
inhibitor of Syk (R406) suppressed the severity of arthri-
tis, bone erosions, pannus development and synovitis in
murine collagen-induced arthritis (CIA)[26]. The
reduced expression of SyK in the R788-treated mice cor-
related with an amelioration of clinical arthritis, a reduc-
tion in proinflammatory chemokines and cytokines,
including the CXCR2 ligand KC-GRO-a,m a c r o p h a g e
chemoattractant protein-1 (MCP-1), IL-1, and IL-6, as
well as inducing suppression of cartilage oligomeric
matrix protein release, the latter protein a sensitive in
vitro biomarker for articular cartilage extracellular
matrix degradation. Because of the apparent successful
preclinical response to R788 in the well-validated CIA
animal model of RA, a Phase II clinical trial involving,
fostamatinib (R406), was conducted.. In addition to
improving clinical outcomes measurements as deter-
mined by the American College of Rheumatology (ACR)
criteria as early as 1 week after oral administration,
R406 also reduced the level of serum IL-6 and MMP-3
(stromelysin-1) in the groups receiving 100 mg and 150
mg of R406 twice daily [27].
In a previous 12-week, ascending-dose, randomized,
placebo-controlled Trial 4 (http://ClinicalTrials.gov
number, NCT00326339) involving 189 patients who had
active RA despite methotrexate therapy, a significant
reduction in arthritis activity and in serum levels of
interleukin-6 and matrix metalloproteinase 3 were seen
in the two groups that received the highest doses of
R788 (100 mg twice daily and 150 mg twice daily), as
compared with the groups that received placebo or the
50-mg dose of R788 twice daily. Notable adverse events
were diarrhea, neutropenia, and an elevation of blood
pressure. In another study to assess the efficacy and
safety of R788, 229 patients with active RA who had
currently or previously failed a biologic therapy were
enrolled in a 3-month double-blind, placebo-controlled
trial of R788. In this study, the primary endpoint was
the ACR 20 response at Month 3. Secondary endpoints
included changes in inflammation and damage assessed
by MRI, and changes in DAS. The ACR 20 response in
the R788 100 mg twice daily (BID) group was 38% ver-
sus 37% in the placebo group at month 3. No significant
differences were achieved in the ACR 20/50/70 levels at
3 months. There were differences between the groups in
secondary endpoints from Baseline to month 3 in CRP
and synovitis scores on MRI. There were baseline differ-
ences in steroid use, prior biologic use, and synovitis
scores by MRI between the R788 group versus placebo
which may have affected the outcomes. A high placebo
response rate was seen in this trial and exploratory ana-
lysis suggests this may in part have been driven by
patients who entered the trial with an elevated erythro-
cyte sedimentation rate, but normal c-reactive protein
[28]. A phase 2 study was conducted to evaluate the effi-
cacy and safety of R788, in patients with active RA
despite methotrexate therapy. Patients (458) who had
active RA despite long-term methotrexate therapy in a
6-month trial were enrolled in a double-blind, placebo-
controlled trial. The primary outcome was the ACR20
response at month 6. A clinically significant effect was
noted by the end of the first week of treatment. Adverse
effects included diarrhea, upper respiratory infections,
hypertension and neutropenia. This study indicated that
R788 reduced disease activity in patients with RA with
adverse events including diarrhea, hypertension, and
neutropenia [29]. Although R788 was effective in the
reduction of disease activity in patients with RA, there is
a high potential for adverse events including neutrope-
nia and infections. As Syk has been reported to have a
role in hematopiesis, neutropenia side effects can be
explained by the inhibition of Syk [30]. In addition, the
specificity of the kinase inhibitor is doubtful as the
active form of this kinase inhibitor (R406) has been
reported to also target the Lyn and Lck kinases in addi-
tion to Syk [31]. As Lck is a critical kinase in T cell line-
age commitment, inhibition of Lck might suppress
immunity, resulting in a high risk for infections [32].
Furthermore, as suppression of Lyn has been reported
to play a role in an antibody-mediated autoimmune dis-
ease resembling systemic lupus erythematosus in mice,
inhibition of Lyn might increase the risk for the devel-
opment of lupus [33]. On the other hand, R788 has
been shown to reduce the development of nephritis in
model mice of human lupus [34]. Therefore, as we indi-
cated, further studies are indeed needed to assess the
safety of this Syk inhibitor [35].
Kinases involved in NF-B signaling pathway
The NF-B family of transcriptional activators regulates
the expression of a variety of cytokines involved in the
Okamoto and Kobayashi Journal of Inflammation 2011, 8:21
http://www.journal-inflammation.com/content/8/1/21
Page 4 of 7pathology of RA, including IL-1, TNF-a, and IL-6 [36].
In most cells, NF-B complexes are located largely in
the cytoplasm. In response to pro-inflammatory cyto-
k i n e ss u c ha sT N F - a and IL-1b, the inhibitory proteins
IB, become phosphorylated by the IBk i n a s e( I K K )
complex on two serine residues located in the N-term-
inal region [37], which results in their rapid ubiquitina-
tion and proteolysis by the 26S proteasome, thereby
allowing the liberated NF-B to translocate to the
nucleus (Figure 1)[38]. The IKK complex consists of two
catalytic subunits, IKKa and IKKb,a n dar e g u l a t o r y
subunit IKKc [39-42]. The kinase activity of both IKKa
and IKKb is induced by a wide variety of NF-Bi n d u -
cers such as TNF-a or IL-1b, and mediated by upstream
kinases including NIK and the extracellular signal-regu-
lated kinase kinase kinase 1, 3 [43-45].
The role of NF-B in the pathogenesis of RA has been
described previously. Mice lacking functional NF-B-
inducing kinase have been shown to be resistant to anti-
gen-induced arthritis [46]. Constitutively active STAT-6,
which blocks NF-B activation has also been shown to
inhibit inflammatory arthritis in mice [46]. Local treat-
ment with the selective IB kinase beta inhibitor
NEMO-binding domain peptide has been shown to
ameliorate rat adjuvant arthritis [47]. We also have
shown that a peroxisome proliferator-activated receptor-
alpha ligand, fenofibrate, inhibited rat adjuvant arthritis
[48]. Therefore, NF-B, which is responsible for the pro-
duction of inflammatory molecules, as well as for the
differentiation of osteoclasts, is an important target for
RA therapy. Fasudil hydrochloride (Fasudil) (1-(5-Isoqui-
nolinesulfonyl)-homopiperazine hydrochloride) is a ser-
ine/threonine kinase inhibitor [49,50] and is the first
kinase inhibitor drug used in a clinical setting in Japan
[51]. Fasudil has been used for years for the treatment
of subarachnoid hemorrhage and its safety in clinical
settings is well established. Fasudil has been reported to
inhibit NF-B signaling following infection by the
human immunodeficiency virus [52].
We found that systemic administration of fasudil, a
novel serine/threonine kinase inhibitor, inhibits the
development of adjuvant-induced arthritis in rats
through the inhibition of the NF-B activation pathway.
We demonstrated that fasudil inhibites cytokine produc-
tion from fibroblast-like synoviocytes, adhesion molecule
expression on human endothelial cells in culture, and
inhibition of NF-B without showing inhibition of either
IBa degradation or nuclear translocation of NF-B.
However fasudil inhibited IL-1b induced NF-B transac-
tivation as well as DNA binding of NF-B. In addition,
in vivo studies have shown that fasudil suppresses the
development of arthritis in an adjuvant-induced arthritis
model [53]. These results indicate that fasudil inhibits
the NF-B signaling required for the binding of NF-B
to specific DNA sequences. Consequently our results
indicate that fasudil might function by inhibiting the
phosphorylation of p65 or a novel NF-B kinase [53].
Conclusion
The lack of clinical efficacy and the high rate of adverse
events seen in the p38 MAPK inhibitor trials highlight
several problems in designing drugs that target these
critical intracellular signaling pathways. First, the struc-
tural similarity of many kinases calls into question the
true specificity of the drugs that target them. Off-target
effects may account for many of the adverse effects
observed. Second, the importance of these pathways in
host defense against disease has naturally resulted in sig-
naling redundancy. Thus, inhibition of one signaling
component may be compensated for by the modification
of complementary pathways. Therefore, lack of specifi-
city may result in off-target effects causing increased
side effects, however absolute specificity may result in a
lack of efficacy due to redundancy in signaling. Towards
increasing kinase inhibitor specificity, we previously
reported that a pseudo-substrate peptide for cyclin-
dependent kinase 7 inhibits transcriptional activation by
the Tat protein of the human immunodeficiency virus
[54,55]. A similar approach may be useful in the inhibi-
tion of kinases important for RA therapy.
Cellular signal transduction pathways including var-
ious transcription factors play critical roles in regulating
the functions of immune effector cells, including expres-
sion of cytokines/chemokines and also in the control of
synovial cell apoptosis. Growing experimental evidence
emphasizes the importance of NF-B, NFAT, JAK/
STAT and other transcription factors in RA. Therefore,
signaling cascades associated with these transcription
factors are possible targets for a comprehensive anti-RA
strategy. New therapeutic strategies may target tran-
scription factor activity by controlling their synthesis or
modulating protein-protein interactions in the activating
signaling cascade. Specific inhibitors have already
reported, for example: a small molecule inhibitor of
NFAT, decoy oligonucleotides for NF-B, interfering
RNAs targeting components of the STAT pathway, and
inhibition of Toll-like receptor signalling pathway by
Chaperonin 10 [56-60]. However, most of the intracellu-
lar kinases that activate transcription factors involved in
RA have pleiotropic roles in other biological processes
and therefore, inhibition of these transcription factors
might invite unexpected side effects in vivo. Clinical and
molecular studies must be undertaken in tandem in
order to develop effective and safe therapeutic strategies
against RA. It is our hope that an orally administered,
small molecule tyrosine kinase inhibitor, with minimal
adverse side-effects will be available in the near future
for treatment of RA. This treatment should be cheaper
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ease outcomes leading to greater patient acceptance.
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